Literature DB >> 27798457

Refractory versus resistant hypertension.

Mohammed Siddiqui1, David A Calhoun.   

Abstract

PURPOSE OF REVIEW: Refractory hypertension is a recently proposed phenotype of antihypertensive treatment failure. As such it represents an extreme subtype of resistant or difficult-to-treat hypertension. Resistant hypertension is relatively common with an estimated prevalence of 10-20% of treated hypertensive patients. It is typically defined as having an uncontrolled blood pressure on three or more antihypertensive medications, including a diuretic. Refractory hypertension is rare with a prevalence of approximately 5% of patients with uncontrolled resistant hypertension. It is defined as an uncontrolled blood pressure with the use of five or more antihypertensive medications, including a long-acting thiazide diuretic, such as chlorthalidone, and a mineralocorticoid receptor antagonist such as spironolactone. RECENT
FINDINGS: Persistent excess fluid retention is thought to commonly underlie development of resistant hypertension, recent studies suggest that refractory may be more likely attributable to heightened sympathetic output as opposed to inappropriate fluid retention.
SUMMARY: Treatment recommendations for resistant hypertension are generally based on intensification of diuretic therapy, especially with combined use of chlorthalidone and spironolactone. Although fuller elucidation is needed, such an approach may not be appropriate for refractory hypertension, which instead, may require effective sympathetic inhibition, either with medications or device-based approaches.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27798457     DOI: 10.1097/MNH.0000000000000286

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  10 in total

1.  [Therapy-resistant and therapy-refractory arterial hypertension].

Authors:  M Wallbach; M J Koziolek
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

Review 2.  Controlled Versus Uncontrolled Resistant Hypertension: Are They in the Same Bag?

Authors:  J C Yugar-Toledo; V Brunelli; J F Vilela-Martin; A Fattori; H Moreno
Journal:  Curr Hypertens Rep       Date:  2018-03-27       Impact factor: 5.369

Review 3.  Hypertension: a new treatment for an old disease? Targeting the immune system.

Authors:  Gisele Facholi Bomfim; Stefany Bruno Assis Cau; Alexandre Santos Bruno; Aline Garcia Fedoce; Fernando S Carneiro
Journal:  Br J Pharmacol       Date:  2018-07-31       Impact factor: 8.739

4.  Refractory Hypertension: a Narrative Systematic Review with Emphasis on Prognosis.

Authors:  Giovanna Bacan; Angélica Ribeiro-Silva; Vinicius A S Oliveira; Claudia R L Cardoso; Gil F Salles
Journal:  Curr Hypertens Rep       Date:  2022-02-02       Impact factor: 5.369

5.  Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.

Authors:  Elizabeth do Espirito Santo Cestário; Letícia Aparecida Barufi Fernandes; Luiz Tadeu Giollo-Júnior; Jéssica Rodrigues Roma Uyemura; Camila Suemi Sato Matarucco; Manoel Idelfonso Paz Landim; Luciana Neves Cosenso-Martin; Lúcia Helena Bonalume Tácito; Heitor Moreno; José Fernando Vilela-Martin; Juan Carlos Yugar-Toledo
Journal:  Trials       Date:  2018-02-12       Impact factor: 2.279

Review 6.  Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.

Authors:  Juan Carlos Yugar-Toledo; Rodrigo Modolo; Ana Paula de Faria; Heitor Moreno
Journal:  Vasc Health Risk Manag       Date:  2017-10-16

7.  Resistant and refractory hypertension: two sides of the same disease?

Authors:  Elizabeth Silaid Muxfeldt; Bernardo Chedier; Cibele Isaac Saad Rodrigues
Journal:  J Bras Nefrol       Date:  2018-12-06

8.  Prevalence, risk factors and impact on outcomes of 30-day unexpected rehospitalization in incident peritoneal dialysis patients.

Authors:  Jianbo Li; Jing Yu; Naya Huang; Hongjian Ye; Dan Wang; Yuan Peng; Xiaobo Guo; Chunyan Yi; Xiao Yang; Xueqing Yu
Journal:  BMC Nephrol       Date:  2021-01-06       Impact factor: 2.388

Review 9.  O-Linked β-N-Acetylglucosamine Modification: Linking Hypertension and the Immune System.

Authors:  Rinaldo Rodrigues Dos Passos Junior; Gisele Facholi Bomfim; Fernanda R Giachini; Rita C Tostes; Victor Vitorino Lima
Journal:  Front Immunol       Date:  2022-03-17       Impact factor: 7.561

Review 10.  Recent advances in understanding and managing resistant/refractory hypertension.

Authors:  Michael Doumas; Konstantinos P Imprialos; Manolis S Kallistratos; Athanasios J Manolis
Journal:  F1000Res       Date:  2020-03-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.